AbbVie Inc (ABBV)
170.46
+0.11
(+0.06%)
USD |
NYSE |
Nov 14, 11:57
AbbVie Research and Development Expense (Quarterly): 2.13B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.13B |
| June 30, 2024 | 1.948B |
| March 31, 2024 | 1.939B |
| December 31, 2023 | 2.705B |
| September 30, 2023 | 1.723B |
| June 30, 2023 | 1.733B |
| March 31, 2023 | 2.292B |
| December 31, 2022 | 2.033B |
| September 30, 2022 | 1.654B |
| June 30, 2022 | 1.878B |
| March 31, 2022 | 1.642B |
| December 31, 2021 | 2.232B |
| September 30, 2021 | 2.063B |
| June 30, 2021 | 1.899B |
| March 31, 2021 | 1.852B |
| December 31, 2020 | 2.19B |
| September 30, 2020 | 1.751B |
| June 30, 2020 | 2.435B |
| March 31, 2020 | 1.379B |
| December 31, 2019 | 1.681B |
| September 30, 2019 | 2.285B |
| June 30, 2019 | 1.382B |
| March 31, 2019 | 1.444B |
| December 31, 2018 | 6.795B |
| September 30, 2018 | 1.323B |
| Date | Value |
|---|---|
| June 30, 2018 | 1.322B |
| March 31, 2018 | 1.313B |
| December 31, 2017 | 1.72B |
| September 30, 2017 | 1.228B |
| June 30, 2017 | 1.244B |
| March 31, 2017 | 1.142B |
| December 31, 2016 | 1.249B |
| September 30, 2016 | 1.186B |
| June 30, 2016 | 1.194B |
| March 31, 2016 | 956.00M |
| December 31, 2015 | 1.075B |
| September 30, 2015 | 1.418B |
| June 30, 2015 | 1.004B |
| March 31, 2015 | 938.00M |
| December 31, 2014 | 907.00M |
| September 30, 2014 | 1.12B |
| June 30, 2014 | 850.00M |
| March 31, 2014 | 772.00M |
| December 31, 2013 | 846.00M |
| September 30, 2013 | 934.00M |
| June 30, 2013 | 779.00M |
| March 31, 2013 | 634.00M |
| December 31, 2012 | 709.00M |
| September 30, 2012 | 813.00M |
| June 30, 2012 | 752.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.379B
Minimum
Mar 2020
2.705B
Maximum
Dec 2023
1.958B
Average
1.919B
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.45B |
| Johnson & Johnson | 4.952B |
| Eli Lilly and Co | 2.734B |
| Merck & Co Inc | 5.862B |
| Pfizer Inc | 2.598B |